SEARCH

SEARCH BY CITATION

References

  • 1
    Maisel A, Mueller C, Adams K, Jr., et al. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824839.
  • 2
    Wess G, Butz V, Mahling M, et al. Evaluation of N-terminal pro-B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers. Am J Vet Res 2011;72:642649.
  • 3
    Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008;232:14961503.
  • 4
    Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res 2007;68:4247.
  • 5
    Singletary GE, Morris NA, Lynne O'Sullivan M, et al. Prospective evaluation of NT-proBNP assay to detect occult dilated cardiomyopathy and predict survival in Doberman Pinschers. J Vet Intern Med 2012;26:13301336.
  • 6
    O'Sullivan ML, O'Grady MR, Minors SL. Plasma big endothelin-1, atrial natriuretic peptide, aldosterone, and norepinephrine concentrations in normal Doberman Pinschers and Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med 2007;21:9299.
  • 7
    Tidholm A, Häggström J, Hansson K. Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs. Am J Vet Res 2001;62:961967.
  • 8
    Takemura N, Toda N, Miyagawa Y, et al. Evaluation of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations in dogs with mitral valve insufficiency. J Vet Med Sci 2009;71:925929.
  • 9
    Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009;180:195201.
  • 10
    Wolf J, Gerlach N, Weber K, et al. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease. J Vet Cardiol 2012;14:399408.
  • 11
    Häggström J, Hansson K, Kvart C, et al. Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease. J Vet Cardiol 2000;2:716.
  • 12
    Reynolds CA, Brown DC, Rush JE, et al. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: The PREDICT cohort study. J Vet Cardiol 2012;14:193202.
  • 13
    Chetboul V, Serres F, Tissier R, et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009;23:984994.
  • 14
    Serres F, Pouchelon JL, Poujol L, et al. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol 2009;11:103121.
  • 15
    Hezzell MJ, Boswood A, Chang YM, et al. The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. J Vet Intern Med 2012;26:302311.
  • 16
    Moonarmart W, Boswood A, Luis Fuentes V, et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010;51:8496.
  • 17
    Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2008;49:2632.
  • 18
    DeFrancesco TC, Rush JE, Rozanski EA, et al. Prospective clinical evaluation of an ELISA B-type natriuretic peptide assay in the diagnosis of congestive heart failure in dogs presenting with cough or dyspnea. J Vet Intern Med 2007;21:243250.
  • 19
    Prosek R, Sisson DD, Oyama MA, et al. Distinguishing cardiac and noncardiac dyspnea in 48 dogs using plasma atrial natriuretic factor, B-type natriuretic factor, endothelin, and cardiac troponin-I. J Vet Intern Med 2007;21:238242.
  • 20
    Oyama MA, Rush JE, Rozanski EA, et al. Assessment of serum N-terminal pro-B-type natriuretic peptide concentration for differentiation of congestive heart failure from primary respiratory tract disease as the cause of respiratory signs in dogs. J Am Vet Med Assoc 2009;235:13191325.
  • 21
    Saito Y, Nakao K, Itoh H, et al. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Comm 1989;158:360368.
  • 22
    Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195203.
  • 23
    Thibault G, Garcia R, Gutkowska J, et al. The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. Biochem J 1987;241:265272.
  • 24
    Winters CJ, Sallman AL, Baker BJ, et al. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438449.
  • 25
    Sagnella GA. Measurement and importance of plasma brain natriuretic peptide and related peptides. Ann Clin Biochem 2001;38:8393.
  • 26
    Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice. Clin Sci 1999;97:689695.
  • 27
    Morgenthaler NG, Struck J, Thomas B, et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234236.
  • 28
    Pemberton CJ, Johnson ML, Yandle TG, et al. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000;36:355359.
  • 29
    Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci 1998;95:519529.
  • 30
    Ettinger SJ, Farace G, Forney SD, et al. Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease. J Am Vet Med Assoc 2012;240:171180.
  • 31
    Balion CM, Santaguida P, McKelvie R, et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin Biochem 2008;41:231239.
  • 32
    Kellihan HB, Oyama MA, Reynolds CA, et al. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol 2009;11(Suppl 1):S93S97.
  • 33
    Lequarre AS, Andersson L, Andre C, et al. LUPA: A European initiative taking advantage of the canine genome architecture for unravelling complex disorders in both human and dogs. Vet J 2011;189:155159.
  • 34
    Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247252.
  • 35
    Hansson K, Häggström J, Kvart C, et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in Cavalier King Charles Spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002;43:568575.
  • 36
    Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocrinol 1997;47:287296.
  • 37
    Mueller T, Gegenhuber A, Dieplinger B, et al. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942944.
  • 38
    Schellenberg S, Grenacher B, Kaufmann K, et al. Analytical validation of commercial immunoassays for the measurement of cardiovascular peptides in the dog. Vet J 2008;178:8590.
  • 39
    Bland M. Multifactorial methods. In: Bland M, ed. An Introduction to Medical Statistics, 2nd ed. Oxford: Oxford University Press; 1995:322323.
  • 40
    Parker HG, Ostrander EA. Canine genomics and genetics: Running with the pack. PLoS Genet 2005;1:e58.
  • 41
    Bodey AR, Michell AR. Epidemiological study of blood pressure in domestic dogs. J Small Anim Pract 1996;37:116125.
  • 42
    Rasmussen CE, Vesterholm S, Ludvigsen TP, et al. Holter monitoring in clinically healthy Cavalier King Charles Spaniels, Wire-haired Dachshunds, and Cairn Terriers. J Vet Intern Med 2011;25:460468.
  • 43
    Höglund K, Hanås S, Carnabuci C, et al. Blood pressure, heart rate, and urinary catecholamines in healthy dogs subjected to different clinical settings. J Vet Intern Med 2012;26:13001308.
  • 44
    Walsh KP, Williams TD, Spiteri C, et al. Role of atrial pressure and rate in release of atrial natriuretic peptide. Am J Physiol 1988;254:R607R610.
  • 45
    Crozier IG, Ikram H, Nicholls MG. The pattern of atrial natriuretic peptide release during ventricular tachycardia in man. Clin Exp Pharmacol Physiol 1987;14:597604.
  • 46
    Luchner A, Borgeson DD, Grantham JA, et al. Relationship between left ventricular wall stress and ANP gene expression during the evolution of rapid ventricular pacing-induced heart failure in the dog. Eur J Heart Fail 2000;2:379386.
  • 47
    Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684H1689.
  • 48
    Hess G, Runkel S, Zdunek D, et al. Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): A study in blood donors. Clin Chim Acta 2005;360:187193.
  • 49
    Boswood A, Attree S, Page K. Clinical validation of a proANP 31-67 fragment ELISA in the diagnosis of heart failure in the dog. J Small Anim Pract 2003;44:104108.
  • 50
    Eriksson AS, Jarvinen AK, Eklund KK, et al. Effect of age and body weight on neurohumoral variables in healthy Cavalier King Charles Spaniels. Am J Vet Res 2001;62:18181824.